Literature DB >> 9827789

Heartburn requiring frequent antacid use may indicate significant illness.

M Robinson1, D Earnest, S Rodriguez-Stanley, B Greenwood-Van Meerveld, P Jaffe, M T Silver, C S Kleoudis, L E Wilson, R H Murdock.   

Abstract

BACKGROUND: Many otherwise healthy individuals with episodic heartburn self-medicate with over-the-counter antacids. We evaluated clinical characteristics of subjects who had never been medically diagnosed as having any upper gastrointestinal tract disorder and who used antacids for symptomatic relief of heartburn. SUBJECTS AND METHODS: Subjects with at least 3 months of frequent heartburn relieved by antacids, and with heartburn on at least 4 of 7 days during the week prior to study entry, had their medical history and gastrointestinal pathological characteristics recorded. Tests included esophagogastroduodenoscopy, esophageal motility and sensitivity studies, and 24-hour pH monitoring.
RESULTS: Of 178 subjects screened, 13 were excluded on the basis of other gastrointestinal diseases at baseline, including diffuse esophageal spasm, peptic ulcer disease, dysplastic columnar metaplasia of the esophagus (Barrett's esophagus), and adenocarcinoma. Ten subjects were ineligible because of insufficient baseline heartburn. The remaining 155 eligible subjects had heartburn for an average of 11 years. Forty-seven percent had daily symptoms and 70% described heartburn severity as moderate, even though on endoscopy most (53%) had normal-appearing esophageal mucosa (grade 0 or 1). Esophageal acid sensitivity was present in 86% of subjects. Mean lower esophageal sphincter pressures and esophageal contractile amplitudes were at the lower limits of normal and total esophageal acid contact time was slightly increased.
CONCLUSIONS: Chronic heartburn can reflect a wide range of diagnostic findings, including important underlying pathological features, and may warrant a full medical examination to detect such abnormal conditions and to permit selection of appropriate therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9827789     DOI: 10.1001/archinte.158.21.2373

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  13 in total

1.  What is heartburn worth? A cost-utility analysis of management strategies.

Authors:  G R Heudebert; R M Centor; J C Klapow; R Marks; L Johnson; C M Wilcox
Journal:  J Gen Intern Med       Date:  2000-03       Impact factor: 5.128

2.  Validity of endoscopic classification of nonerosive reflux disease.

Authors:  Takashi Joh; Hiroto Miwa; Kazuhide Higuchi; Tomohiko Shimatani; Noriaki Manabe; Kyoichi Adachi; Tsuneya Wada; Makoto Sasaki; Yasuhiro Fujiwara; Michio Hongo; Tsutomu Chiba; Yoshikazu Kinoshita
Journal:  J Gastroenterol       Date:  2007-06-29       Impact factor: 7.527

Review 3.  Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs.

Authors:  J Dent; D Armstrong; B Delaney; P Moayyedi; N J Talley; N Vakil
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

4.  Nonerosive Reflux Disease (NERD) - An Update.

Authors:  Tiberiu Hershcovici; Ronnie Fass
Journal:  J Neurogastroenterol Motil       Date:  2010-01-31       Impact factor: 4.924

5.  Gastroesophageal reflux in children: pathogenesis, prevalence, diagnosis, and role of proton pump inhibitors in treatment.

Authors:  Benjamin D Gold; James W Freston
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 6.  Treatment for Barrett's oesophagus.

Authors:  Jonathan Re Rees; Pierre Lao-Sirieix; Angela Wong; Rebecca C Fitzgerald
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

7.  Lifestyle factors associated with gastroesophageal reflux disease in the Japanese population.

Authors:  Nobuyuki Matsuki; Tsuyoshi Fujita; Naoya Watanabe; Atsushi Sugahara; Akihiko Watanabe; Tsukasa Ishida; Yoshinori Morita; Masaru Yoshida; Hiromu Kutsumi; Takanobu Hayakumo; Hidekazu Mukai; Takeshi Azuma
Journal:  J Gastroenterol       Date:  2012-08-22       Impact factor: 7.527

8.  Managing gastroesophageal reflux disease in children: The role of endoscopy.

Authors:  Helena As Goldani; Daltro La Nunes; Cristina T Ferreira
Journal:  World J Gastrointest Endosc       Date:  2012-08-16

Review 9.  Gastro-oesophageal reflux disease in Asia : birth of a 'new' disease?

Authors:  Ting K Cheung; Benjamin C Y Wong; Shiu K Lam
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 10.  Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.

Authors:  Kirsten E Sigterman; Bart van Pinxteren; Peter A Bonis; Joseph Lau; Mattijs E Numans
Journal:  Cochrane Database Syst Rev       Date:  2013-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.